2022-P: Patient Perspectives and Experience with Ready-to-Use Glucagon

Introduction and Objective: Historically, published patient perspectives on ready-to-use (RTU) glucagon have been based on product descriptions alone, mainly qualitative with smaller samples sizes. The objective of this quantitative study was to obtain patient perspectives on RTU glucagon based on real-world, practical usage experiences of people with diabetes (PWD). Methods: A total of 192 past RTU glucagon users were invited, via email, to take a double-blinded, quantitative survey about product perceptions and usage experiences from Aug. 15 - Sept. 3, 2025. Results were quantified and analyzed using descriptive statistics at the 90% and 95% confidence interval. Results: There were 127 U.S-based respondents [50 Gvoke Hypopen® users, 77 nasal glucagon users] ages 20 - 65+ years. Most respondents had T1D (81%) while 19% had T2D. Overall, 58 - 69% of respondents were “highly worried” about severe hypoglycemia (SH) and 95% of recent RTU glucagon users say it is important to have on-hand. Before using RTU glucagon, 40% experienced symptoms such as shaking, sweating, dizziness, and/or behavioral changes. About 40% of nasal glucagon users listed at least one side effect as severe vs. 26% Gvoke Hypopen® users. Gvoke Hypopen® received higher satisfaction ratings than nasal glucagon on the following product attributes: (1) ease of opening packaging; (2) intuitiveness of administration; (3) ease of self-administration; (4) ease of confirming full-dose was administered; (5) speed in bringing blood glucagon back to normal; (6) convenience of having on-hand. Conclusion: Overall respondents gave higher satisfaction ratings for Gvoke Hypopen® than nasal glucagon. PWD who have used RTU glucagon within the last year recognize the importance of having it on-hand for SH. Awareness of PWD perceptions and practical usage experience can help healthcare providers tailor discussions and recommendations to the specific needs of both patients and their caregivers. Disclosure N. Ferguson: None. M.C. Devona: Employee; Current; Xeris Pharmaceuticals, Inc. J. Hantrakul: Employee; Current; Xeris Pharmaceuticals, Inc.